Haemonetics Corporation (HAE)
Solvency ratios
| Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | |
|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 2.99 | 2.29 | 2.37 | 2.48 | 2.49 |
Haemonetics Corporation's solvency ratios indicate a strong financial position with consistently low leverage and debt levels. The debt-to-assets, debt-to-capital, and debt-to-equity ratios have all remained at 0.00% from March 31, 2021, to March 31, 2024, suggesting that the company operates with minimal debt relative to its assets and capital structure.
Additionally, the financial leverage ratio has slightly decreased from 2.49 in 2021 to 2.29 in 2024, indicating that the company relies more on equity financing rather than debt to support its operations. However, please note that data for March 31, 2025, is not available.
Overall, Haemonetics Corporation's solvency ratios reflect a conservative approach to managing its financial obligations, which may indicate lower financial risk and greater stability in the face of economic uncertainties.
Coverage ratios
| Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | |
|---|---|---|---|---|---|
| Interest coverage | 0.00 | 12.93 | 10.67 | 4.72 | 3.44 |
Haemonetics Corporation's interest coverage ratio has exhibited variability over the years. As of March 31, 2021, the interest coverage ratio stood at 3.44, indicating the company's ability to cover its interest expenses approximately three times. By March 31, 2022, this ratio improved to 4.72, suggesting a better ability to meet its interest obligations. The trend continued positively, with the interest coverage ratio soaring to 10.67 by March 31, 2023, and further to 12.93 by March 31, 2024, signaling a significant enhancement in the company's ability to cover interest payments.
However, a notable anomaly is observed on March 31, 2025, where the interest coverage ratio is shown as 0.00. This implies that Haemonetics Corporation's earnings were not sufficient to cover its interest expenses for that period. It is crucial for the company to investigate the reasons behind this sudden drop in the interest coverage ratio and take necessary measures to ensure a healthy and sustainable level of interest coverage in the future.